Oppenheimer Downgrades Bio-Reference Laboratories (BRLI) to Perform
More News related to BRLI
- Bio-Reference Laboratories, Inc. Again Awarded New York State Department of Corrections Laboratory Services Contract
- SmallCapSentinel.com: Records and Revenues
- BioReference Laboratories, Inc to Speak at the Oppenheimer 20th Annual Health Care Conference
- Practice Fusion and BioReference Laboratories Team to Offer Free Electronic Health Records to Physicians
- BioReference Laboratories, Inc to Speak at the UBS Global Life Sciences Conference
More News related to Downgrades
- Canaccord Adams Downgrades Golden Star Resources Ltd. (GSS) to Hold
- Barrington Downgrades Perceptron (PRCP) Following Q1 Miss
- DA Davidson Issues Mid-Day Downgrade on FEI Company (FEIC)
- D.A. Davidson Downgrades Sterling Construction (STRL) to Neutral
- BMO Capital Downgrades MF Global (MF) to Market Perform
Oppenheimer downgrades Bio-Reference Laboratories (Nasdaq: BRLI) from Outperform to Perform. Price target $25.
Bio-Reference Laboratories, Inc. is an independent regional clinical laboratory servicing the greater New York metropolitan area.
Related Categories
DowngradesStocks Mentioned
-0.45Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
